Setmelanotide
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
Rhythm · Phase 3 · Completed · Enrollment 52
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Setmelanotide (Double-Blind) | 7 participants | 7 participants | 2 participants | n/r | 0 |
| Placebo (Double-Blind) | 6 participants | 0 participants | 1 participants | n/r | 0 |
| Setmelanotide (Open-label) | 8 participants | 8 participants | 7 participants | n/r | 0 |
| Pivotal Cohort | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.